JP Morgan Chase’s Viking Therapeutics VKTX Stock Holding History

JP Morgan Chase’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$898K	Buy	+30,000	New	+$964K	﹤0.01%	4672
2025 Q4	–	Sell	-13,000	Closed	-$342K	–	7807
2025 Q3	$342K	Sell	13,000 -37,000	-74%	-$1.1M	﹤0.01%	5241
2025 Q2	$1.32M	Buy	+50,000	New	+$1.32M	﹤0.01%	4214
2025 Q1	–	Sell	-40,000	Closed	-$1.61M	–	7759
2024 Q4	$1.61M	Sell	40,000 -120,000	-75%	-$6.84M	﹤0.01%	4309
2024 Q3	$10.1M	Buy	+160,000	New	+$9.39M	﹤0.01%	2594
2024 Q1	–	Sell	-7,200	Closed	-$134K	–	7921
2023 Q4	$134K	Hold	7,200	–	–	﹤0.01%	5601
2023 Q3	$79.7K	Sell	7,200 -837,300	-99%	-$12M	﹤0.01%	5618
2023 Q2	$13.7M	Buy	+844,500	New	+$17.7M	﹤0.01%	2014
2020 Q1	–	Sell	-194,400	Closed	-$1.56M	–	5755
2019 Q4	$1.56M	Hold	194,400	–	–	﹤0.01%	3563
2019 Q3	$1.34M	Sell	194,400 -27,700	-12%	-$206K	﹤0.01%	3672
2019 Q2	$1.86M	Sell	222,100 -36,500	-14%	-$312K	﹤0.01%	3435
2019 Q1	$2.57M	Buy	+258,600	New	+$2.16M	﹤0.01%	3164
2018 Q4	–	Sell	-30,000	Closed	-$523K	–	5962
2018 Q3	$523K	Buy	+30,000	New	+$357K	﹤0.01%	4257

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase's VKTX Position: Q1 2026 in Review

JP Morgan Chase reduced its Viking Therapeutics (VKTX) stake by 11% in Q1 2026, selling an estimated $1.96M and leaving 485,703 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

JP Morgan Chase first reported a position in VKTX in Q2 2018 and has held it in 32 quarters since. The position peaked at $134M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

JP Morgan Chase held 485,703 shares of Viking Therapeutics worth $14.5M as of Q1 2026.
JP Morgan Chase sold 61,125 Viking Therapeutics shares in Q1 2026, an estimated $1.96M.
Viking Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2355 holding.
JP Morgan Chase first reported a position in Viking Therapeutics in Q2 2018 and has held it in 32 quarters since.
JP Morgan Chase's Viking Therapeutics position peaked at $134M in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.